Gevokizumab

N/A

Report date: 2024/02/26 11:15:13

Base Information

Drug NameGevokizumab
Drug Alias NameGevokizumabum吉伏珠单抗gevokizumab格沃吉珠单抗XMA-005.2 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-1 beta inhibitors
TargetsInterleukin-1 beta
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Pyoderma Gangrenosum +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumArmenia +[31] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesXoma Corp
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesUniversity of ZurichInstitut De Recherches Internationales ServierLes Laboratoires Servier Industrie +[9] 
Active IndicationsStomach NeoplasmsColorectal NeoplasmsEsophageal Neoplasms +[4] 
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Pyoderma Gangrenosum +[13] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG